- In October 2023, Alnylam Pharmaceuticals, Inc. announced the publication of results from APOLLO-B Phase 3 study of patisiran in patients with the cardiomyopathy of ATTR amyloidosis. The study reported that the patisiran preserved functionality capacity, health status, and quality of life compared with placebo at 12 months.
